1. Intratumoral Pi deprivation can benefit chemoembolization therapy by increasing the accumulation of intracellular doxorubicin.
2. Sevelamer, a polymeric phosphate binder, was used as an embolic agent to induce intratumoral inorganic phosphate (Pi) starvation.
3. In vitro tests showed that Pi starvation increased the cellular accumulation of DOX and enhanced cytotoxicity and cell apoptosis by suppressing the expression of ABC transporters.
The article is generally reliable and trustworthy, as it provides evidence for its claims through experiments conducted in both animal models and in vitro tests. The authors also provide detailed descriptions of their methods and results, which allows readers to assess the validity of their findings. Furthermore, the authors declare no conflicts of interest in this work, which further adds to the trustworthiness of the article.
However, there are some potential biases that should be noted when assessing this article. Firstly, the authors only present one side of the argument – that intratumoral Pi deprivation can benefit chemoembolization therapy – without exploring any counterarguments or alternative perspectives on this issue. Additionally, while the authors provide evidence for their claims through experiments conducted in both animal models and in vitro tests, they do not discuss any possible risks associated with these treatments or explore any other potential implications of their findings. Finally, while the authors declare no conflicts of interest in this work, they do not mention whether any funding sources were involved in conducting these experiments or writing up this article; thus it is unclear if there may be any promotional content present within this article that could potentially influence its conclusions.